分子靶向药物治疗肝细胞癌的研究进展

梁源; 王世明; 师振茗

doi:10.3969/j.issn.1001-5256.2016.02.03.045

分子靶向药物治疗肝细胞癌的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.02.03.045

山西医科大学第一医院普外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2038
- HTML全文浏览量: 15
- PDF下载量: 418
- 被引次数: 0
出版历程
- 出版日期: 2016-03-20

Research advances in application of molecular- targeted therapy for hepatocellular carcinoma

Department of General Surgery, The First Hospital of Shanxi Medical University

摘要

摘要:
肝细胞癌(HCC)严重威胁着人类的生命健康。在临床治疗中,HCC治疗策略的选择越来越备受关注,随着对HCC发病机制的不断研究及分子生物学技术的飞速发展,分子靶向抗肿瘤药物治疗晚期HCC成为研究热点,并在临床实践中取得了显著疗效。回顾了近几年HCC分子靶向治疗药物最新临床应用研究进展及出现的相关问题,并针对其治疗策略的未来焦点进行展望,为应用研究和临床治疗HCC提供新的方向和参考。
- 癌,肝细胞 /
- 药物疗法 /
- 综述
Abstract:
Hepatocellular carcinoma( HCC) greatly threatens human health. In clinical treatment,the therapeutic strategies for HCC are attracting more attention. With the research advances in the pathogenesis of HCC and the rapid development of molecular biology techniques,the therapies with molecular- targeted antitumor drugs for advanced HCC have become a hot research topic,and significant efficacy has been achieved in clinical practice. This article summarizes the research advances in clinical application of molecular- targeted drugs for the treatment of HCC and related issues,discusses the future perspectives of therapeutic strategies,and provides a new direction and reference for the clinical treatment of HCC.
- carcinoma hepatocellular /
- drug targeted therapy /
- review

HTML全文

参考文献(26)

[1] JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.

[2]FU X,HE J,SHI J,et al.Clinical value of morphological classification of hepatocellular carcinoma[J].Chin J Dig Surg,2015,14(2):120-126.(in Chinese)伏旭,何健,史烔,等.肝细胞癌大体形态分型的临床意义[J].中华消化外科杂志,2015,14(2):120-126.

[3] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[4]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.

[5]FAIVRE S,RAYMOND E,BOUCHER E,et al.Safety and efficacy of sunitinib in patients with advanced hepato cellularcarcinoma:an open-label,multicentre,phaseⅡstudy[J].Lancet Oncol,2009,10(8):794-800.

[6]CHENG A,KANG Y,LIN D,et al.PhaseⅢtrial of sunitinib versus sorafenib in advanced hepatocellular carcinoma(HCC)[J].J Clin Oncol,2011,29(15):2696.

[7]QI XS,JIA J,HAN GH,et al.Sunitinib for Treatment of Hepatocellular Carcinoma:an Overview of Clinical Trials[J].Chin J Gastroenterol,2014,19(3):169-172.(in Chinese)祁兴顺,贾佳,韩国宏,等.舒尼替尼治疗肝细胞癌的临床研究现状[J].胃肠病学,2014,19(3):169-172.

[8]BRUIX J,TAK WY,GABARRINI A,et al.Regorafenib as secondline therapy for intermediate or advanced hepatocellular carcinoma:multicentre,open-label,phaseⅡsafety study[J].Eur J Cance,2013,49(16):3412-3419.

[9]CHENG AL,FINNR S,KUDO M,et al.Regorafenib(REG)in patients with hepatocellular carcinoma(HCC)progressing following sorafenib:an ongoing randomized,doubleblind,phaseⅢtrial[J].J Clin Oncol,2013,31(Suppl 15):4163.

[10]QI XS,JIA J,LIU L,et al.Regorafenib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].J Clin Hepatol,2014,30(3):225-227.(in Chinese)祁兴顺,贾佳,刘雷,等.Regorafenib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2014,30(3):225-227.

[11]TOH HC,CHEN PJ,CARR BI,et al.Phase 2 trial of linifanib(ABT-869)in patients with unresectable or metastatic hepatocellular carcinoma[J].Cancer,2013,119(2):380-387.

[12]CAINAP C,QI S,HUANG WT,et al.Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phaseⅢtrial[J].J Clin Oncol,2015,33(2):172-179.

[13]HU FR,GAO F,QI XS.Advances in clinical research on linifanib in treatment of liver cancer[J].World Chin J Dig,2015,23(16):2568-2573.(in Chinese)胡凤蓉,高帆,祁兴顺.Linifanib治疗肝癌的临床研究进展[J].世界华人消化杂志,2015,23(16):2568-2573.

[14]PHILIP PA,MAHONEY MR,ALLMER C,et al.Phase II study of Erlotinib(OSI-774)in patients with advanced hepatocellular cancer[J].J Clin Oncol,2005,23(27):6657-6663.

[15]ZHU AX,ROSMORDUC O,EVANS TR,et al.SEARCH:a phase III,randomized,doubleblind,placebocontrolled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(6):559-566.

[16]GAO F,QI XS.Clinical research progress in Erlotinib treatment for hepatocellular carcinoma[J].J Clin Hepatol,2015,31(6):985-988.(in Chinese)高帆,祁兴顺.Erlotinib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2015,31(6):985-988.

[17]JOJNSON PJ,QIN S,PARK JW,et al.Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized phaseⅢBRISK-FL study.[J].J Clin Oncol,2013,31(28):3517-3524.

[18]LLOVET JM,DECAENS T,RAOUL JL,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phaseⅢBRISK-PS study[J].J Clin Oncol,2013,31(28):3509-3516.

[19]QI XS,YANG M,BAI W,et al.Brivanib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].J Clin Hepatol,2014,30(3):222-224.(in Chinese)祁兴顺,杨曼,白苇,等.Brivanib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2014,30(3):222-224.

[20]SANTORO A,RIMASSA L,BORBATH I,et al.Tivantinib for second-line treatment of advanced hepatocellular carcinoma:a randomised,placebo-controlled phase 2 study[J].Lancet Oncol,2013,14(1):55-63.

[21]QI XS,GUO XZ,HAN GH,et al.MET inhibitors for treatment of advanced hepatocellular carcinoma:a review[J].World J Gastroenterol,2015,21(18):5445-5453.

[22]SANTORO A,PORTA C,RIMASSA L,et al.Metiv-HCC:a phaseⅢclinical trial evaluating tivantinib(ARQ 197),a MET inhibitor,versus placebo as second-line in patients(pts)with MET-high inoperable hepatocellular carcinoma(HCC)[C]//ALEXANDRIA,VA 22314 USA:ASCO,2013,31(15).

[23]GOVINAERAJAN R,SIEGEL E,MAKHOUL I,et al.Bevacizumab and erlotinibin previously untreated inoperable and metastatic hepatocellular carcinoma[J].Am J Clin Oncol,2013,36(3):254-257.

[24]QIN S,BAI Y,LIM HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31(28):3501-3508.

[25]ZHAO Y,WANG WJ,GUAN S,et al.Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma:a large-scale multicenter study of 222 patients[J].Ann Oncol,2013,24(7):1786-1792.

[26]BRUIX J,TAKAYANA T,MAZZAFERRO V,et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM):a phase 3,randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2015,16(13):1344-1354.

施引文献

资源附件(0)

访问统计